Protagonist Therapeutics, Inc PTGX
$140.90
-0.68%
at last close
Analyst Consensus
- Consensus Rating
- Buy (14 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $144.29
- Implied Upside
- +2.4%
- Price Target Range
- $82.00 – $190.00
- Analysts (12 mo)
- 14
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-09-01 | BarclaysEtzer Darout |
Maintains | Overweight | $153 → $180 |
| 2026-09-01 | BMO CapitalEtzer Darout |
Maintains | Outperform | $178 → $190 |
| 2026-08-31 | CitigroupGeoff Meacham |
Maintains | Buy | $175 → $182 |
| 2026-08-31 | HC Wainwright & Co.Douglas Tsao |
Maintains | Buy | $167 → $170 |
| 2026-08-17 | BMO CapitalEtzer Darout |
Maintains | Outperform | $112 → $178 |
| 2026-08-10 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $145 → $170 |
| 2026-08-10 | WedbushYun Zhong |
Maintains | Outperform | $118 → $173 |
| 2026-08-10 | Goldman Sachs Richard Law |
Upgrades | Neutral → Buy | $110 → $186 |
| 2026-08-06 | CitigroupGeoff Meacham |
Maintains | Buy | $130 → $175 |
| 2026-08-06 | BarclaysEtzer Darout |
Maintains | Overweight | $151 → $153 |
| 2026-07-14 | BarclaysEtzer Darout |
Maintains | Overweight | $119 → $151 |
| 2026-07-07 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $121 → $145 |
| 2026-05-06 | CitizensJonathan Wolleben |
Maintains | Market outperform | $120 → $137 |
| 2026-05-06 | WedbushYun Zhong |
Maintains | Outperform | $112 → $118 |
| 2026-04-15 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $110 → $121 |
| 2026-04-07 | Clear StreetKaveri Pohlman |
Maintains | Buy | $104 → $116 |
| 2026-03-19 | Leerink PartnersFaisal Khurshid |
Maintains | Outperform | $107 → $110 |
| 2026-03-19 | JP MorganBrian Cheng |
Maintains | Overweight | $95 → $106 |
| 2026-03-19 | CitigroupGeoff Meacham |
Maintains | Buy | $115 → $125 |
| 2026-03-19 | BarclaysEtzer Darout |
Maintains | Overweight | $113 → $119 |
| 2026-03-03 | Goldman Sachs Richard Law |
Maintains | Neutral | $65 → $95 |
| 2026-02-26 | TD CowenTara Bancroft |
Maintains | Buy | $90 → $100 |
| 2026-02-26 | BarclaysEtzer Darout |
Maintains | Overweight | $108 → $113 |
| 2026-02-26 | CitizensJonathan Wolleben |
Maintains | Market outperform | $102 → $112 |
| 2026-02-02 | JefferiesRoger Song |
Maintains | Buy | $95 → $118 |
| 2026-01-30 | HC Wainwright & Co.Douglas Tsao |
Maintains | Buy | $80 → $117 |
| 2026-01-05 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $88 → $110 |
| 2025-12-17 | BarclaysEtzer Darout |
Maintains | Overweight | $88 → $108 |
| 2025-12-08 | CitigroupGeoff Meacham |
Maintains | Buy | $98 → $115 |
| 2025-11-10 | CitigroupGeoff Meacham |
Maintains | Buy | $96 → $98 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $140.90
- Market Cap
- $9.18 billion
- 52-Week Range
- $54.50 – $160.81
- Average Volume
- 602K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.